XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Acquisitions (Narrative) (Details)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2021
USD ($)
right
$ / shares
Feb. 29, 2020
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Business Acquisition [Line Items]          
Acquired IPR&D Expense     $ 299.3 $ 52.3  
Cash paid, net of cash acquired     747.4 849.3  
Goodwill     3,877.4   $ 3,766.5
Repayments of long-term debt     $ 0.0 $ 276.3  
Prevail Therapeutics Inc.          
Business Acquisition [Line Items]          
Business acquisition, share price (in dollars per share) | $ / shares $ 22.50        
Cash paid, net of cash acquired $ 747.4        
Consideration transferred, number of contingent value rights | right 1        
Contingent value right, additional price per share (up to) (in dollars per share) | $ / shares $ 4.00        
Contingent value right, additional price per share, aggregate amount $ 160.0        
Contingent value right, monthly reduction (in cents per share) | $ / shares $ 0.083        
Goodwill $ 111.0        
Acquired IPR&D 834.0        
Deferred income taxes assumed $ 100.2        
Dermira          
Business Acquisition [Line Items]          
Purchase price   $ 849.3      
Goodwill   86.8      
Acquired IPR&D   1,200.0      
Deferred income taxes assumed   49.5      
Long-term debt assumed   $ 375.5      
Repayments of long-term debt         $ 276.2